How successful has targeted RNA interference for hepatic fibrosis been?

References

• Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013 May;123(5):1887–1901.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014 Sep 18;12:e145.
   PubMed Web of Science ®Google Scholar
• Lurie Y, Webb M, Cytter-Kuint R, et al. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015 Nov 07;21(41):11567–11583.
   PubMed Web of Science ®Google Scholar
• Bansal R, Nagorniewicz B, Prakash J. Clinical advancements in the targeted therapies against liver fibrosis. Mediators Inflamm. 2016 Nov 24;2016:e7629724.
   PubMedGoogle Scholar
• Ikenaga N, Peng ZW, Vaid KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017;10:e312473.
   Google Scholar
• Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.
   PubMedGoogle Scholar
• A study of FG-3019 in subjects with liver fibrosis due to chronic hepatitis B infection. US National Library of Medicine: ClinicalTrialsgov, 2010. cited 2016 Aug 16. Available from: https://clinicaltrials.gov/ct2/show/NCT01217632?term=NCT01217632&rank=1
   Google Scholar
• Simtuzumab (GS-6624) in the treatment of cirrhosis due to NASH (NASH). US National Library of Medicine: ClinicalTrialsgov, 2012. cited 2017 Feb 24; Available from: https://clinicaltrials.gov/ct2/show/NCT01672879?term=NCT01672879&rank=1
   Google Scholar
• Fowell AJ, Collins JE, Duncombe DR, et al. Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation. Biochem Biophys Res Commun. 2011 Apr 08;407(2):277–282.
   PubMed Web of Science ®Google Scholar
• Khaja F, Jayawardena D, Kuzmis A, et al. Targeted sterically stabilized phospholipid siRNA nanomedicine for hepatic and renal fibrosis. Nanomaterials. 2016 Jan 05;6(1):e8.
   Web of Science ®Google Scholar
• Kong WH, Park K, Lee MY, et al. Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis. Biomaterials. 2013 Jan;34(2):542–551.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu F, Ding F, et al. Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro. Mol Med Rep. 2015 Sep;12(3):3453–3461.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li L. Adenovirus-mediated RNA interference against collagen-specific molecular chaperone 47-KDa heat shock protein suppresses scar formation on mouse wounds. Cell Biol Int. 2008 May;32(5):484–493.
   PubMed Web of Science ®Google Scholar
• Xu W, Wang LW, Shi JZ, et al. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice. Hbpd Int. 2009 Jun;8(3):300–308.
   Google Scholar
• Yuhua Z, Wanhua R, Chenggang S, et al. Disruption of connective tissue growth factor by short hairpin RNA inhibits collagen synthesis and extracellular matrix secretion in hepatic stellate cells. Liver Int. 2008 May;28(5):632–639.
   PubMed Web of Science ®Google Scholar
• Yang D, Gao YH, Tan KB, et al. Inhibition of hepatic fibrosis with artificial microRNA using ultrasound and cationic liposome-bearing microbubbles. Gene Ther. 2013 Dec;20(12):1140–1148.
   PubMed Web of Science ®Google Scholar
• Ely A, Naidoo T, Arbuthnot P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009 Jul;37(13):e91.
   PubMed Web of Science ®Google Scholar
• Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006 May 25;441(7092):537–541.
   PubMed Web of Science ®Google Scholar
• Maepa MB, Ely A, Grayson W, et al. Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary microRNAs. Mol Ther Nucleic Acids. 2017 Jun;16(7):190–199.
   Google Scholar
• McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol. 2003 Jun;21(6):639–644.
   PubMed Web of Science ®Google Scholar
• Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013 May;21(5):973–985.
   PubMed Web of Science ®Google Scholar
• Bourhill T, Arbuthnot P, Ely A. Successful disabling of the 5ʹ UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics. J Virol Methods. 2016 Sep;235:26–33.
   PubMed Web of Science ®Google Scholar
• Dallas A, Ilves H, Ma H, et al. Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. J Virol. 2014 May;88(9):4647–4656.
   PubMed Web of Science ®Google Scholar
• Khaliq S, Jahan S, Ijaz B, et al. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch Virol. 2011 Mar;156(3):433–442.
   PubMed Web of Science ®Google Scholar
• Khaliq S, Jahan S, Pervaiz A, et al. Down-regulation of IRES containing 5ʹUTR of HCV genotype 3a using siRNAs. Virol J. 2011 May 13;8:e221.
   PubMed Web of Science ®Google Scholar
• Pei Z, Shi G, Kondo S, et al. Adenovirus vectors lacking virus-associated RNA expression enhance shRNA activity to suppress hepatitis C virus replication. Sci Rep. 2013 Dec 20;3:e3575.
   PubMed Web of Science ®Google Scholar
• Suhy DA, Kao SC, Mao T, et al. Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Therapy: Journal Am Soc Gene Ther. 2012 Sep;20(9):1737–1749.
   PubMed Web of Science ®Google Scholar
• Torrecilla J, Del Pozo-Rodriguez A, Solinis MA, et al. Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES). Colloids Surf B Biointerfaces. 2016 Oct 01;146:808–817.
   PubMed Web of Science ®Google Scholar
• Bobbin ML, Rossi JJ. RNA Interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56:103–122.
   PubMed Web of Science ®Google Scholar
• Hu PF, Chen H, Zhong W, et al. Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol. 2009 Jul;51(1):102–113.
   PubMed Web of Science ®Google Scholar
• Bangen JM, Hammerich L, Sonntag R, et al. Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice. Hepatology. 2017 Oct;66(4):1242–1257.
   PubMed Web of Science ®Google Scholar
• Liu CH, Chan KM, Chiang T, et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis. Mol Pharm. 2016 Jul 05;13(7):2253–2262.
   PubMedGoogle Scholar
• Marimani MD, Ely A, Buff MC, et al. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. J Control Release. 2015 Jul;10(209):198–206.
   Google Scholar
• Mowa MB, Crowther C, Ely A, et al. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014;2014:e718743.
   PubMedGoogle Scholar
• Huang G, Brigstock DR. Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci (Landmark Ed). 2012 Jun 01;17:2495–2507.
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008 Apr;19(2):133–144.
   PubMed Web of Science ®Google Scholar
• Onozuka I, Kakinuma S, Kamiya A, et al. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem Biophys Res Commun. 2011 Mar 04;406(1):134–140.
   PubMed Web of Science ®Google Scholar
• Cong M, Liu T, Wang P, et al. Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis. Am J Pathol. 2013 May;182(5):1607–1616.
   PubMed Web of Science ®Google Scholar
• Hu Y-B, Li D-G, Lu H-M. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J Gene Med. 2007 Mar;9(3):217–229.
   PubMed Web of Science ®Google Scholar
• Zhan SS, Jiang JX, Wu J, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006 Mar;43(3):435–443.
   PubMed Web of Science ®Google Scholar
• Eguchi A, De Mollerat Du Jeu X, Johnson CD, et al. Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. J Hepatol. 2016 Mar;64(3):699–707.
   PubMed Web of Science ®Google Scholar
• Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7797–7802.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yang XF. Progress of targeting transforming growth factor-beta1 small interfering RNA in liver fibrosis. Chinese Medical Sciences Journal = Chung-Kuo Hsueh K’o Hsueh Tsa Chih. 2014 Dec;29(4):231–235.
   PubMedGoogle Scholar
• Cheng K, Yang N, Mahato RI. TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm. 2009 May-Jun;6(3):772–779.
   PubMedGoogle Scholar
• Lang Q, Liu Q, Xu N, et al. The antifibrotic effects of TGF-beta1 siRNA on hepatic fibrosis in rats. Biochem Biophys Res Commun. 2011 Jun 10;409(3):448–453.
   PubMed Web of Science ®Google Scholar
• Kim KH, Kim HC, Hwang MY, et al. The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun. 2006 May 19;343(4):1072–1078.
   PubMed Web of Science ®Google Scholar
• Kim J-Y, An H-J, Kim W-H, et al. Anti-fibrotic effects of synthetic oligodeoxynucleotide for TGF-β1 and smad in an animal model of liver cirrhosis. Mol Ther Nucleic Acids. 2017;8:250–263.
   PubMedGoogle Scholar
• Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008 Apr;26(4):431–442.
   PubMed Web of Science ®Google Scholar
• Phase A, Randomized, double-blind, placebo-controlled escalating single dose study to evaluate the safety, tolerability and pharmacokinetics of ND-L02-s0201 injection in normal healthy subjects. US National Library of Medicine: ClinicalTrialsgov, 2013. cited 2017 May 11; Available from: https://clinicaltrials.gov/ct2/show/NCT01858935?term=NCT01858935&rank=1
   Google Scholar
• Phase 1b/2, open label, repeat dose, dose escalation study of ND-L02-s0201 injection in subjects with moderate to extensive fibrosis (METAVIR F3-4). US National Library of Medicine: ClinicalTrialsgov, 2014. cited 2017 May 11; Available from: https://clinicaltrials.gov/ct2/show/NCT02227459?term=NCT02227459&rank=1
   Google Scholar
• Safety and efficacy study of single doses of TT-034 in patients with chronic hepatitis C. US National Library of Medicine: ClinicalTrialsgov, 2016. cited 2016 Nov 30; Available from: https://clinicaltrials.gov/ct2/show/NCT01899092?term=NCT01899092&rank=1
   Google Scholar
• Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. Qjm. 2013 Feb;106(2):153–163.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A Randomized Trial. Ann Intern Med. 2015 Jul 7;163(1):1–13.
   PubMed Web of Science ®Google Scholar
• Study of ARC-520 in patients with chronic hepatitis B virus. US National Library of Medicine: ClinicalTrialsgov, 2014. cited 2017 Jun 27; Available from: https://clinicaltrials.gov/ct2/show/study/NCT02065336?term=NCT02065336&rank=1
   Google Scholar
• A study of ALN-HBV in healthy adult volunteers and non-cirrhotic patients with chronic hepatitis B virus (HBV) infection. US National Library of Medicine: ClinicalTrialsgov, 2016. cited 2017 Nov 7; Available from: https://clinicaltrials.gov/ct2/show/NCT02826018?term=NCT02826018&rank=1
   Google Scholar
• Study of ARB-001467 in subjects with chronic HBV infection receiving nucleos(t)ide analogue therapy. US National Library of Medicine: ClinicalTrialsgov, 2015. cited 2017 Apr 14; Available from: https://clinicaltrials.gov/ct2/show/NCT02631096?term=NCT02631096&rank=1
   Google Scholar
• Arbuthnot P, Ely A, Weinberg MS. Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther. 2009 Apr;9(2):91–103.
   PubMed Web of Science ®Google Scholar
• Villemejane J, Mir LM. Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol. 2009 May;157(2):207–219.
   PubMed Web of Science ®Google Scholar
• Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Therapy: Journal Am Soc Gene Ther. 2007 Dec;15(12):2063–2069.
   PubMed Web of Science ®Google Scholar
• Sato A, Takagi M, Shimamoto A, et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials. 2007 Mar;28(7):1434–1442.
   PubMed Web of Science ®Google Scholar
• Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):12982–12987.
   PubMed Web of Science ®Google Scholar
• Greupink R, Bakker HI, Bouma W, et al. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J Pharmacol Exp Ther. 2006 May;317(2):514–521.
   PubMed Web of Science ®Google Scholar
• Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem. 2010 Nov 17; 21(11):2119–2127.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Ise H, Kim E, et al. Imaging and therapy of liver fibrosis using bioreducible polyethylenimine/siRNA complexes conjugated with N-acetylglucosamine as a targeting moiety. Biomaterials. 2013 Sep;34(27):6504–6514.
   PubMed Web of Science ®Google Scholar
• Toriyabe N, Sakurai Y, Kato A, et al. The delivery of small interfering RNA to hepatic stellate cells using a lipid nanoparticle composed of a vitamin A-Scaffold lipid-like material. J Pharm Sci. 2017 Apr 27;106(8):2046–2052.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li Y, Jain A, et al. Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. Nanomedicine. 2017. published online 7 September 2017. DOI:10.1016/j.nano.2017.08.017.
   Web of Science ®Google Scholar
• Chen Z, Liu H, Jain A, et al. Discovery of aptamer ligands for hepatic stellate cells using SELEX. Theranostics. 2017;7(12):2982–2995.
   PubMed Web of Science ®Google Scholar
• Nakatani T, Kuriyama S, Tominaga K, et al. Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut. 2000 Oct;47(4):563–570.
   PubMed Web of Science ®Google Scholar
• Mowa MB, Crowther C, Ely A, et al. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna. 2012;1(1):19–25.
   PubMedGoogle Scholar
• Conlon TJ, Cossette T, Erger K, et al. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Mol Therapy: Journal Am Soc Gene Ther. 2005 Nov;12(5):867–875.
   PubMed Web of Science ®Google Scholar
• Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005 Jun;11(6):875–888.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Iimuro Y, Fujimoto J, et al. Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis. Gut. 2007 Mar;56(3):396–404.
   PubMed Web of Science ®Google Scholar
• Chen S-W, Chen Y-X, Zhang X-R, et al. Targeted inhibition of platelet-derived growth factor receptor-beta subunit in hepatic stellate cells ameliorates hepatic fibrosis in rats. Gene Ther. 2008 Nov;15(21):1424–1435.
   PubMed Web of Science ®Google Scholar
• Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol Therapy: Journal Am Soc Gene Ther. 2012 Mar;20(3):483–512.
   PubMed Web of Science ®Google Scholar
• Kang SH, Revuri V, Lee S-J, et al. Oral siRNA delivery to treat colorectal liver metastases. ACS Nano. 2017 Oct 13;11:10417–10429.
   PubMed Web of Science ®Google Scholar